Ernexa Therapeutics (ERNAW) Cash from Investing Activities (2010 - 2026)
Ernexa Therapeutics (ERNAW) reported Cash from Investing Activities of -$2000.0 for Q1 2026, up 86.67% quarter-over-quarter from -$15000.0 in Q4 2025.
Ernexa Therapeutics (ERNAW) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Ernexa Therapeutics has reported Cash from Investing Activities for 17 years, with the latest figure at -$2000.0 in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities changed N/A year-over-year to -$2000.0; the trailing twelve-month figure through Mar 2026 stood at -$36000.0 (changed N/A YoY), and the FY2025 full-year result was -$37000.0, up 89.86% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at -$2000.0, up from -$15000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $129000.0 in Q4 2022, with the low at -$249000.0 in Q2 2024.
- Historically, Cash from Investing Activities has averaged -$44800.0 across 5 years, with a median of -$31000.0 in 2022.
- The largest YoY upside for Cash from Investing Activities was 187.76% in 2022 against a maximum downside of 8600.0% in 2022.
- Ernexa Therapeutics' Cash from Investing Activities stood at $129000.0 in 2022, then slumped by 114.73% to -$19000.0 in 2023, then changed by 0.0% to -$19000.0 in 2024, then grew by 21.05% to -$15000.0 in 2025, then soared by 86.67% to -$2000.0 in 2026.
- The last three Cash from Investing Activities figures came in at -$2000.0 (Q1 2026), -$15000.0 (Q4 2025), and -$19000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Ernexa Therapeutics | - | - | - | -2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Dec 31, 2025 | -15,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Sep 30, 2024 | -19,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -97,000.00 |
| Mar 31, 2024 | -97,000.00 |
| Dec 31, 2023 | -19,000.00 |
| Dec 31, 2023 | -19,000.00 |
| Dec 31, 2022 | 129,000.00 |
| Dec 31, 2022 | 129,000.00 |
| Sep 30, 2022 | -43,000.00 |
| Sep 30, 2022 | -43,000.00 |
| Jun 30, 2022 | -87,000.00 |
| Jun 30, 2022 | -87,000.00 |
| Mar 31, 2022 | -46,000.00 |
| Mar 31, 2022 | -46,000.00 |